Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Neoplastic Cells, Circulating 1Fatigue 1Cardiotoxicity 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 8Doxorubicin 8Exercise 7Cyclophosphamide 6Echocardiography 5Carvedilol 5Docetaxel 4Tablets 2Silymarin 2Radiotherapy 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Exercise Test 2Epirubicin 2Bisoprolol 2Atorvastatin 2Anthracyclines 2sacubitril and valsartan sodium hydrate drug combination 1nicotinamide-beta-riboside 1mitoquinone 1epicatechin gallate 1empagliflozin 1dapagliflozin 1candesartan 1Watchful Waiting 1Therapeutics 1Taxes 1Tamoxifen 1Social Determinants of Health 1Secondary Prevention 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiotoxicity × Reverse Transcriptase Polymerase Chain Reaction × Breast × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡